12,580 results match your criteria Cutaneous T-Cell Lymphoma


Mycosis fungoides and gastric T-cell lymphoma: A case report.

Mol Clin Oncol 2020 Sep 6;13(3):15. Epub 2020 Jul 6.

Department of Health Sciences, University 'Magna Græcia' of Catanzaro, Catanzaro I-88100, Italy.

Mycosis fungoides (MF) is a cutaneous malignant lymphoma with an extended clinical course. MF presents in series of dermatological manifestations, beginning with patches and plaques of the skin, and eventually evolving into tumours. Often MF can occur for extended periods without worsening of external symptoms, while the disease advances internally in organs such as lymph nodes, liver, spleen, lung, bone marrow, gastrointestinal tract, pancreas and kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2020.2085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391825PMC
September 2020

LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.

Acta Pharmacol Sin 2020 Aug 3. Epub 2020 Aug 3.

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 211198, China.

Cutaneous T-cell lymphoma (CTCL) is characterized by a heterogeneous group of extranodal non-Hodgkin lymphomas, in which monoclonal T lymphocytes infiltrate the skin. LW-213, a derivative of wogonin, was found to induce cell apoptosis in chronic myeloid leukemia (CML). In this study, we investigated the effects of LW-213 on CTCL cells and the underlying mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41401-020-0466-7DOI Listing

Pruritus in Black Skin: Unique Molecular Characteristics and Clinical Features.

J Natl Med Assoc 2020 Jul 31. Epub 2020 Jul 31.

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Background: Chronic pruritus dramatically disrupts quality of life, impairs sleep, and is difficult to treat. The pathogenesis and severity of chronic itch can vary significantly with race. Black skin has inherent structural and molecular characteristics that exacerbates pruritus, leading to unique presentations of pruritic conditions and added challenges in finding effective therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jnma.2020.07.002DOI Listing

T-Cell Lymphoblastic Lymphoma/Leukemia Presenting as a Diffuse Viral Exanthem-like Reaction: A Clinical and Histopathological Challenge.

Am J Dermatopathol 2020 Jul 23. Epub 2020 Jul 23.

Pathology and Dermatology, University of Virginia, Charlottesville VA.

Cutaneous involvement by leukemia, or leukemia cutis, is a rare manifestation of leukemic disorders, most frequently occurring in children. The skin findings, which usually include multiple violaceous or erythematous nodules on the face, most often follow the classic presenting signs and symptoms of leukemia and occur in patients with an established primary diagnosis. Patients with T-cell acute lymphoblastic leukemia and associated leukemia cutis typically present with a solitary firm red to bluish nodule, often with an accompanying mediastinal mass, that can produce respiratory symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001766DOI Listing

Disparities in Outcomes of CD8 Cutaneous T Cell Lymphoma by Race and Presenting Lesion Location.

Br J Dermatol 2020 Jul 30. Epub 2020 Jul 30.

Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.

While cutaneous T-cell lymphoma (CTCL) presents most commonly with a CD4 phenotype, CD8 and CD30 variants have also been described. CD8 variants include primary cutaneous epidermotropic cytotoxic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous CD8 lymphomas associated with immunodeficiency, and CD8 variants of other well-defined CTCLs . While the epidemiology of other CTCLs has been well described, there remains a dearth of literature characterizing the incidence and survival patterns of CD8 CTCL . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19426DOI Listing

[Primary cutaneous CD4+ small to medium-sized T-cell lymphoma in an adolescent patient].

HNO 2020 Jul 29. Epub 2020 Jul 29.

Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland.

A rare finding of primary cutaneous CD4+ small to medium-sized T‑cell lymphoma (SMPTCL) in a fifteen-year-old patient is reported. This is a rare tumor entity for which there is currently no standardized treatment recommendation. At the interdisciplinary tumor board, the decision was made to resect the tumor and reconstruct the defect with a nasolabial advancement flap in a two-stage process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00106-020-00912-2DOI Listing

Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.

Dermatol Ther 2020 Jul 28:e14099. Epub 2020 Jul 28.

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Mogamulizumab is a humanized anti-C-C chemokine receptor type (CCR)4 antibody that shows cytotoxicity against CCR4+ lymphoma cells via antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T cell lymphoma (CTCL) patients. The production levels of ligands for CCR4, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.14099DOI Listing

Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis.

Front Med (Lausanne) 2020 25;7:290. Epub 2020 Jun 25.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been proposed as curative approach for advanced cutaneous T-cell lymphomas (CTCL). Currently, there is no established consensus for the management of disease relapse after alloHSCT. Ten patients, previously treated with multiple lines of systemic treatment, received alloHSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344271PMC

Hypopigmented Mycosis Fungoides: Loss of Pigmentation Reflects Antitumor Immune Response in Young Patients.

Cancers (Basel) 2020 Jul 22;12(8). Epub 2020 Jul 22.

Division of Experimental Medicine, McGill University, Montreal, QC H4A3J1, Canada.

Hypopigmented mycosis fungoides (HMF) is a form of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of extranodal non-Hodgkin's lymphomas. HMF has a unique set of defining features that include light colored to achromic lesions, a predilection for darker skin phototypes, an early onset of disease, and predominance of CD8 T-cells, among others. In the current review, we detail the known pathways of molecular pathogenesis for this lymphoma and posit that an active Th1/cytotoxic antitumor immune response in part explains why this variant is primarily seen in children/adolescents and young adults, who do not exhibit signs of immunosenescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12082007DOI Listing

Vorinostat as potential antiparasitic drug.

Eur Rev Med Pharmacol Sci 2020 Jul;24(13):7412-7419

Instituto de Farmacobiología, Universidad de la Cañada, Paraje Titlacuatitla, Teotitlán de Flores Magón, Oaxaca, México.

Objective: Vorinostat is a drug used to treat cutaneous T cell lymphoma whose action mechanism is based on Histone Deacetylase inhibition. Histone Deacetylases are a family of enzymes that remove acetyl groups from histone and non-histone proteins that control many crucial processes, such as gene regulation, cell cycle progression, differentiation, and apoptosis. Histone Deacetylase homologues are also expressed in parasites of the genus Plasmodium, Leishmania, Cryptosporidium, Schistosoma, Entamoeba, and others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202007_21909DOI Listing

Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy.

Clin Lymphoma Myeloma Leuk 2020 Jun 30. Epub 2020 Jun 30.

Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address:

Background: Treatment of cutaneous T-cell lymphoma (CTCL) with total skin electron beam (TSEB) therapy has been associated with deep responses but short progression-free intervals. Maintenance therapy might prolong the response duration; however, limited data assessing the outcomes with maintenance therapy after TSEB are available. We evaluated the effect of maintenance therapy on the outcomes for patients with CTCL receiving TSEB therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.06.020DOI Listing

Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.

Int Arch Allergy Immunol 2020 Jul 20:1-13. Epub 2020 Jul 20.

Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland,

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous disease group of unknown etiology with a complex immunological background. As CTCL arises from T cells that have a vital role in the antitumor response, their therapy is largely aimed at reversing the immunological mechanisms leading to or manifesting during this malignancy. Early disease stages can be controlled with skin-directed therapy in most CTCL cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000509281DOI Listing

Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients.

J Dermatol Sci 2020 Jul 9. Epub 2020 Jul 9.

Department of Dermatovenerology, West China Hospital, Sichuan University Chengdu, China. Electronic address:

Background: Hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) encompasses a rare group of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases.

Objective: To define the clinical and pathologic characteristics of HVLPD and to identify mutant genes that may be related to the development of HVLPD.

Methods: Clinical data and archived formalin-fixed, paraffin-embedded tissue were obtained from 19 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.06.013DOI Listing

Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?

Am J Dermatopathol 2020 Jul 14. Epub 2020 Jul 14.

Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI.

Mycosis fungoides (MF) is primarily characterized by epidermotropic CD3+/CD4+/CD45RO+ memory T cells. CD4/CD8 double-negative MF is an uncommon variant with no presumed prognostic significance. Despite the variability in the clinical course and presentation of MF, most cases behave indolently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001725DOI Listing

Atypical BCL6/GATA3+ Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma: A Diagnostic Challenge.

Am J Dermatopathol 2020 Jul 14. Epub 2020 Jul 14.

Departments of Pathology, and.

Primary cutaneous acral CD8-positive T-cell lymphoma consists of slow-growing nodules in acral sites with a histopathology, suggesting high-grade lymphoma despite the indolent clinical course. It has been recently included in WHO-EORTC classification for primary cutaneous lymphomas as a provisional entity. A correct diagnosis of this entity is important because its differential diagnosis include more aggressive cutaneous lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001737DOI Listing

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient.

Mediterr J Hematol Infect Dis 2020 1;12(1):e2020040. Epub 2020 Jul 1.

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

Background: Sézary syndrome (SS) is a rare lymphoproliferative neoplasm, almost incurable outside the setting of allogeneic transplantable patients. The prognosis for relapsed/refractory patients remains poor, as the available drugs confer short-lasting remission. In this setting, the anti-chemokine receptor type 4 (CCR4) monoclonal antibody mogamulizumab demonstrated efficacy in an international, open-label, randomized controlled phase 3 trial (MAVORIC) versus vorinostat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2020.040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340218PMC

Multifocal CD4+ Primary Cutaneous Small/Medium Lymphoproliferative Disorder Successfully Treated With Low-Dose Oral Methotrexate: A Case Report.

Cureus 2020 Jun 9;12(6):e8534. Epub 2020 Jun 9.

Hematology, Schulich School of Medicine and Dentistry, Western University, London, CAN.

Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is a rare indolent disorder often associated with a favourable prognosis. It typically presents as a solitary skin lesion, mainly in the head, neck, or upper trunk region. Multifocal PCSM-LPD is a rare entity, with no standard treatment approaches available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352792PMC

Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review.

SAGE Open Med Case Rep 2020 26;8:2050313X20937223. Epub 2020 Jun 26.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Illinois College of Medicine at Peoria, Peoria, IL, USA.

Immunosuppressive therapy is well recognized as increasing the risk of lymphoma. Mycosis fungoides is a rare cutaneous form of T-cell lymphoma with a largely unknown etiology and not typically associated with immunosuppression. In this article, we describe our encounter with a 24-year-old male with Crohn's disease in remission on immunotherapy, specifically dual therapy with azathioprine and infliximab, presenting with a facial rash found to be consistent with mycosis fungoides on biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X20937223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328350PMC

Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL).

J Med Econ 2020 Jul 25:1-9. Epub 2020 Jul 25.

Acaster Lloyd Consulting Ltd, London, UK.

Aim: Cutaneous T-cell Lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma characterized by skin lesions, which can negatively impact the quality of life of both patients and their caregivers. The Decision Support Unit (DSU) at the National Institute for Health and Care Excellence (NICE) in the UK recently outlined a rationale for the inclusion of caregiver burden in economic evaluations. This study aimed to estimate utilities for health states associated with being a caregiver for an individual with CTCL at different stages of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2020.1793764DOI Listing

Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.

Leuk Lymphoma 2020 Jul 9:1-7. Epub 2020 Jul 9.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

We report results on 23 patients with cutaneous T cell lymphoma (7 primary cutaneous γδ T cell lymphoma [PCGDT], 16 mycosis fungoides/Sézary syndrome [MF/SS]) who underwent allogeneic stem cell transplantation. All pts had skin involvement, 14 had total skin electron beam before conditioning. Donors were 10/10 HLA matched related (13), 5/10 haploidentical (4), and matched unrelated (5) or mismatched unrelated (1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1790555DOI Listing

Interventions for mycosis fungoides.

Cochrane Database Syst Rev 2020 07 7;7:CD008946. Epub 2020 Jul 7.

Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany.

Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, a malignant, chronic disease initially affecting the skin. Several therapies are available, which may induce clinical remission for a time. This is an update of a Cochrane Review first published in 2012: we wanted to assess new trials, some of which investigated new interventions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD008946.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389258PMC

Review of the use of gentian violet in dermatology practice.

Dermatol Online J 2020 May 15;26(5). Epub 2020 May 15.

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC.

Objective: To review the use of gentian violet in dermatology.

Design: A comprehensive literature search on gentian violet in dermatology practice was performed through PubMed.

Results: Gentian violet is effective in treating methicillin-resistant Staphylococcus aureus-colonized skin lesions; mean number of days for complete eradication was 9. Read More

View Article

Download full-text PDF

Source

A case of bullous Sézary syndrome.

Dermatol Online J 2020 Apr 15;26(4). Epub 2020 Apr 15.

University of North Carolina at Chapel Hill, Department of Dermatology, Chapel Hill, NC.

Sézary syndrome is a rare leukemic subtype of cutaneous T cell lymphoma that is characterized by erythroderma, lymphadenopathy, and malignant T cells in the peripheral blood. Poor prognostic factors of Sézary syndrome include advanced disease stage, older age at onset, and large cell transformation. Presentation with bullous lesions, though rare, has been reported in a few patients. Read More

View Article

Download full-text PDF

Source

Intravascular Cutaneous Disorders. A Clinicopathologic Review.

Am J Dermatopathol 2020 Jun 30. Epub 2020 Jun 30.

Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.

Intravascular proliferations of the skin are clinically heterogeneous and may present with a wide range of clinical features, including violaceous papules, nodules, plaques, or other unspecific cutaneous lesions. Histopathologically, these conditions are characterized by proliferation of different cell types within the lumina of dermal vessels and endothelial cell hyperplasia. Immunohistochemistry is the best tool to identify the nature of the intravascular proliferating cells and the type of involved vessel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001706DOI Listing

Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.

Am J Clin Dermatol 2020 Jul 1. Epub 2020 Jul 1.

Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family that plays a critical role in the B-cell receptor signaling pathway. It also induces an 'off-target' inhibition of a range of other kinases including (but not limited to) epidermal growth factor receptor (EGFR), SRC, and other kinases of the TEC family (interleukin-2-inducible T-cell kinase [ITK], Tec, BMX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00535-xDOI Listing

High-Scatter Lymphocytes in the Blood of Erythrodermic Cutaneous T-Cell Lymphoma: Evidence for Large-Cell Transformation?

Clin Lymphoma Myeloma Leuk 2020 May 4. Epub 2020 May 4.

Department of Pathology, Drexel University College of Medicine, Philadelphia, PA. Electronic address:

Background: Erythrodermic cutaneous T-cell lymphoma consists of erythrodermic mycosis fungoides and Sézary syndrome. Previous studies have indicated that very large Sézary cells (> 14 μm diameter) or the presence of aneuploid cells in the blood might reflect large-cell transformation, with a corresponding poor prognosis.

Patients And Methods: A retrospective study assessed data between June 1997 and April 2002 of 32 patients with erythrodermic cutaneous T-cell lymphoma, 4 patients with leukemic mycosis fungoides, and 19 patients with nonneoplastic inflammatory conditions who were referred for evaluation of possible cutaneous T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.04.017DOI Listing

Ki67 and CD31 Differential Expression in Cutaneous T-Cell Lymphoma and Its Mimickers: Association with Clinicopathological Criteria and Disease Advancement.

Clin Cosmet Investig Dermatol 2020 23;13:431-442. Epub 2020 Jun 23.

Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Background: Cell proliferation and angiogenesis are important in progression of cancerous processes. Differentiating cutaneous T-cell lymphoma (CTCL) from its mimicking dermatoses and prognosticating it are challenging.

Aim: This study assesses cell proliferation and angiogenesis in different CTCL subtypes using immunohistochemistry (IHC) for Ki67 and CD31 to testify their usability in differentiating CTCL from mimicking dermatoses and discriminating CTCL subtypes from each other with correlation to clinicopathological parameters and disease advancement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S256269DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320895PMC

Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC.

J Invest Dermatol 2020 Jun 27. Epub 2020 Jun 27.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address:

Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that manifests initially in the skin and disseminates systemically as disease progresses. Mycosis fungoides and Sézary syndrome (MF/SS) are the most common subtypes of CTCL. Advanced MF/SS are life-threatening with few treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.05.110DOI Listing

Tumour-stage mycosis fungoides initially misdiagnosed as Langerhans cell histiocytosis.

Pathology 2020 08 27;52(5):593-596. Epub 2020 Jun 27.

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2020.04.006DOI Listing

Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time.

Transfus Med Hemother 2020 Jun 27;47(3):226-235. Epub 2020 May 27.

Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria.

Extracorporeal photopheresis (ECP) is a cell-based immunotherapy that involves the reinfusion of autologous leukocytes after exposure to psoralen and UVA. The treatment has been used for over 30 years, at first on patients with cutaneous T-cell lymphoma (CTCL) and later for the management of patients with graft-versus-host disease (GvHD), sclerosing disorders, atopic dermatitis, and other diseases that may share the common driving factor of a pathogenic T-cell clone or clones in blood circulation. Patients with clinical improvement mount an antigen-specific immune response that may have tolerance traits in the case of GvHD or anticlonal cytotoxic characteristics in the case of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000508479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315210PMC

Bendamustine Monotherapy for Primary Cutaneous Gamma-Delta T-Cell Lymphoma.

JAMA Dermatol 2020 Jun 17. Epub 2020 Jun 17.

Department of Dermatology, Venereology, and Allergology, HELIOS St Elisabeth Hospital Oberhausen, University Witten/Herdecke, Oberhausen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2020.1231DOI Listing

Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma.

Exp Dermatol 2020 Jun 23. Epub 2020 Jun 23.

Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Background: Systemic chemotherapy is often the last resort of advanced cutaneous T-cell lymphoma (CTCL). Tumor recurrence and adverse effects of systemic chemotherapy are the main limitations.

Objective: We aim to investigate the metabolic alterations in tumor cells after CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.14133DOI Listing

Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.

Oncoimmunology 2020 May 13;9(1):1758869. Epub 2020 May 13.

Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.

Ovarian cancer accounts for most deaths from gynecologic malignancies. Although more than 80% of patients respond to first-line standard of care, most of these responders present with recurrence and eventually succumb to carcinomatosis and chemotherapy-resistant disease. To improve patient survival, new modalities must, therefore, target or prevent recurrent disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2020.1758869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302442PMC

Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.

Oncol Lett 2020 Jul 6;20(1):533-540. Epub 2020 May 6.

Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland.

Histone deacetylase (HDAC) inhibitors, approved for the treatment of cutaneous T-cell lymphoma (CTCL), are non-selective agents associated with an unsatisfactory response and considerable side-effects. Targeting single HDAC isoforms is considered to provide novel therapeutic options. HDAC6 is overexpressed in primary samples from patients with CTCL and preclinical studies using transgenic mice that spontaneously develop a CTCL-like disease, have suggested that combinations including HDAC6 inhibitors may be successful in the treatment of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2020.11587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285804PMC

Potential of Skin Microbiome, Pro- and/or Pre-Biotics to Affect Local Cutaneous Responses to UV Exposure.

Nutrients 2020 Jun 17;12(6). Epub 2020 Jun 17.

Research Unit for Photodermatology, Department of Dermatology, Medical University of Graz, 8010 Graz, Austria.

The human skin hosts innumerable microorganisms and maintains homeostasis with the local immune system despite the challenges offered by environmental factors such as ultraviolet radiation (UVR). UVR causes cutaneous alterations such as acute (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu12061795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353315PMC

Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Leuk Lymphoma 2020 Jun 19:1-7. Epub 2020 Jun 19.

Department of Hematology/Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Patients with CTCL are at increased risk for bacteremia which is a leading cause of morbidity and mortality. We assessed risk factors for and the impact of bacteremia on survival in a retrospective cohort of 188 CTCL patients at a single US academic institution treated between 1990 and 2018. With a median follow up of 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1779259DOI Listing

Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides.

Acta Derm Venereol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Recent studies suggest that folliculotropic mycosis fungoides (FMF), the most common variant of mycosis fungoides (MF), presents with 2 distinct clinicopathological stages: early indolent stage and more aggressive advanced/tumour stage. To further characterize these stages, miR-155 expression was studied with qRT-PCR and found to be significantly higher in biopsies of tumour-stage FMF compared with early-stage FMF and inflammatory dermatoses. There was no statistically significant difference in miR-155 expression between early-stage FMF and early-stage MF, nor between tumour-stage FMF and tumour-stage MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3578DOI Listing
June 2020
3.025 Impact Factor

MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.

Acta Derm Venereol 2020 Jun 18. Epub 2020 Jun 18.

Department of Dermatology, Aarhus University Hospital, P.P. Oerumsgade 11, DK-8200 Aarhus N, Denmark. E-mail:

A prognostic 3-miRNA classifier for early-stage mycosis fungoides has been developed recently, with miR-106b providing the strongest prognostic power. The aim of this study was to investigate the molecular function of miR-106b in mycosis fungoides disease progression. The cellular localization of miR-106b in mycosis fungoides skin biopsies was determined by in situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3574DOI Listing

Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.

Clin Lymphoma Myeloma Leuk 2020 May 11. Epub 2020 May 11.

Yale University, New Haven, CT. Electronic address:

Introduction: We examined patient characteristics, treatments, and outcomes of patients with transformed mycosis fungoides (tMF) from COMPLETE: a large, multicenter, prospective cohort study of peripheral T-cell lymphoma patients in the United States.

Methods: Patients with tMF were enrolled in COMPLETE at the time of transformation. For this analysis, we identified patients with tMF with completed baseline, treatment, and follow-up records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.001DOI Listing

[Facial ulcerated nodules revealing primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma].

Ann Dermatol Venereol 2020 Jun 8. Epub 2020 Jun 8.

Service de dermatologie, CHU de Pontchaillou, rue Henri Le Guillou, 35000 Rennes, France. Electronic address:

Background: Primary cutaneous CD8+ aggressive, epidermotropic, cytotoxic T-cell lymphoma is a rare disease with a poor prognosis. Herein we report a new case, with facial lesions, which was difficult to diagnose.

Patients And Methods: A 39-year-old woman was hospitalized for ulcerated nodules on the face that had been developing rapidly for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2020.04.014DOI Listing

Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.

Cytometry B Clin Cytom 2020 Jun 9. Epub 2020 Jun 9.

Cancer Research Center (IBMCC-CSIC/USAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca, IBSAL and CIBERONC, Salamanca, Spain.

This review discusses the definition and major categories of cutaneous T-cell lymphoma, Sézary syndrome and mycosis fungoides, and the role of immunophenotyping in their diagnosis. The following key points are raised: (a) Sézary syndrome and mycosis fungoides cells most often have a characteristic CD3+ CD4+ CD7- and/or CD26- immunophenotype. (b) This immunophenotype is not specific, but can assist in the distinction from non-neoplastic T cells and other subtypes of mature T-cell neoplasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21888DOI Listing

Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.

Toxicology 2020 Jun 5;441:152507. Epub 2020 Jun 5.

College of Pharmacy, Pharmacology and Toxicology Department, King Saud University, Riyadh, Saudi Arabia.

Vorinostat was approved as the first histone deacetylase inhibitor for the management of cutaneous T cell lymphoma. However, it's in vivo genetic and epigenetic effects on non-cancerous cells remain poorly understood. As genetic and epigenetic changes play a critical role in the pathogenesis of carcinogenesis, we investigated whether vorinostat induces genetic and epigenetic alterations in mouse bone marrow cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tox.2020.152507DOI Listing

Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.

Br J Dermatol 2020 Jun 8. Epub 2020 Jun 8.

Division of Dermatology, Washington University School of Medicine, St Louis, MO, USA.

Background: Cutaneous T-cell lymphoma (CTCL) negatively impacts quality of life (QoL), but existing QoL questionnaires may not comprehensively reflect patients' experience.

Objectives: To identify the aspects of QoL that are most meaningful to patients with CTCL and to evaluate existing QoL instruments in this context.

Methods: Semistructured interviews were conducted between May and June 2019 using purposive sampling of patients with CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19298DOI Listing

Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation.

Case Rep Hematol 2020 16;2020:6309736. Epub 2020 Jan 16.

Haematology Unit, Careggi University Hospital, Florence, Italy.

ALK-negative anaplastic large cell lymphoma is a rare T-cell neoplasm with an aggressive course requiring prompt diagnostic work-up and treatment. Few cases of concomitant multiple myeloma and T-cell neoplasm are described in the literature, mainly regarding primary cutaneous anaplastic large cell lymphoma. We present the case of a 65-year-old man, simultaneously diagnosed with ALK-negative anaplastic large cell lymphoma with extranodal localization in the gastrocnemius muscle (stage 1AE) and IgG lambda multiple myeloma (ISS 2, Durie-Salmon stage 3A). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/6309736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201522PMC
January 2020

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.

Eur J Cancer 2020 Jul 2;133:120-130. Epub 2020 Jun 2.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 1452, Houston, TX, USA. Electronic address:

Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles) versus physician's choice (methotrexate/bexarotene; ≤48 weeks) in the phase III ALCANZA study. Quality of life (QoL) in ALCANZA patients was also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.04.010DOI Listing
July 2020
5.417 Impact Factor

Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma.

Blood Adv 2020 Jun;4(11):2489-2500

Division of Dermatology, Department of Medicine, and.

Mycosis fungoides (MF) is a slowly progressive cutaneous T-cell lymphoma (CTCL) for which there is no cure. In the early plaque stage, the disease is indolent, but development of tumors heralds an increased risk of metastasis and death. Previous research into the genomic landscape of CTCL revealed a complex pattern of >50 driver mutations implicated in more than a dozen signaling pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284100PMC

Total skin electron beam therapy for primary cutaneous T-cell lymphomas: clinical characteristics and outcomes in a Mexican reference center.

Rep Pract Oncol Radiother 2020 Jul-Aug;25(4):562-567. Epub 2020 Apr 27.

Radiotherapy and Medical Physics Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 15 Vasco de Quiroga. Belisario Domínguez Sección XVI, Tlalpan, Mexico.

Aim: The aim of this study was to assess treatment modalities, treatment response, toxicity profile, disease progression and outcomes in 14 patients with a confirmed diagnosis of primary cutaneous T-cell lymphoma (PCTCL) treated with total skin electron beam therapy (TSEBT).

Background: Primary cutaneous lymphomas (PCLs) are extranodal non-Hodgkin lymphomas originating in the skin without evidence of extracutaneous disease at diagnosis. Despite advances in systemic and local therapy options, the management of advanced stages remains mostly palliative. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rpor.2020.03.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256054PMC